April 29, 2024 – We are delighted to share that X4 Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved XOLREMDI™ (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome. This is the first treatment developed specifically for patients living with WHIM syndrome, a rare combined primary immunodeficiency.
“The approval of XOLREMDI is a transformational milestone both for X4 and, more importantly, for the WHIM syndrome community,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
The Jeffrey Modell Foundation is proud to partner with X4 Pharmaceuticals in support of the WHIM syndrome community, and we are thrilled to witness this critical development for patient treatment and care.
Read the full press release here.